Entera Bio (ENTX) Capital Expenditures (2021 - 2025)

Entera Bio (ENTX) has reported Capital Expenditures for 5 consecutive years, with $27000.0 the latest figure, recorded in Q4 2025.

• Quarterly Capital Expenditures rose 800.0% year-over-year to $27000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $99000.0 (up 800.0% YoY) and the FY2025 annual result came in at $107000.0, up 3466.67% from the prior year.
• Capital Expenditures eased to $27000.0 in Q4 2025 per ENTX's latest filing, from $43000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for ENTX reached as high as $43000.0 in Q3 2025 and fell as low as $1000.0 in Q2 2023.
• A 5-year average of $13642.9 and a median of $9000.0 in 2021 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 94.74% — and 2025, when it soared 800.0%.
• Year by year, Capital Expenditures stood at $10000.0 in 2021, then tumbled by 70.0% to $3000.0 in 2022, then soared by 66.67% to $5000.0 in 2023, then slumped by 40.0% to $3000.0 in 2024, then surged by 800.0% to $27000.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $27000.0, $43000.0, and $29000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.